Veritas Investment Management (UK) Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$555K |
| 2 |
Cognizant
CTSH
|
+$211K |
| 3 |
Comcast
CMCSA
|
+$191K |
| 4 |
CVS Health
CVS
|
+$35.6K |
| 5 |
SLB Ltd
SLB
|
+$2.98K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.69M |
| 2 |
Microsoft
MSFT
|
+$2.68M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$1.61M |
| 4 |
Mastercard
MA
|
+$1.36M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$1.13M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.84% |
| 2 | Technology | 24.43% |
| 3 | Financials | 17.75% |
| 4 | Communication Services | 15.45% |
| 5 | Materials | 8.77% |
Similar funds
Veritas Investment Management (UK)'s Q4 2017 Portfolio in Review
As of Q4 2017, Veritas Investment Management (UK) held 51 positions worth $271M, down 4.6% from $284M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Veritas Investment Management (UK) withdrew a net $26.5M in Q4 2017, closing 7 positions and reducing 23 holdings. Its most notable exit was PepsiCo, an estimated $189K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 25% a quarter earlier, followed by Technology and Financials.
Against the trend, Veritas Investment Management (UK) added an estimated $555K to Labcorp.
- Veritas Investment Management (UK) added most to Labcorp in Q4 2017, an estimated $555K increase.
- Veritas Investment Management (UK)'s biggest Q4 2017 reduction was UnitedHealth, cutting an estimated $2.69M.
- Veritas Investment Management (UK) fully exited PepsiCo in Q4 2017, selling an estimated $189K.
- Veritas Investment Management (UK)'s ten largest holdings make up 72% of its $271M portfolio in Q4 2017.
- Veritas Investment Management (UK) opened 0 new positions and closed 7 in Q4 2017.
- Veritas Investment Management (UK)'s portfolio value fell 4.6% quarter-over-quarter to $271M.
Based on Veritas Investment Management (UK)'s 13F filing for Q4 2017, filed 6 Feb 2018.